Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.
Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.
advertisement
Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
How clinical AI models' predictive power can degrade over time
Next article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Guidelines to prevent youth baseball injuries need more muscle
